The European Commission has granted marketing authorization for Wegovy in tablet form, marking a significant milestone for Novo Nordisk’s weight-loss franchise.
The approval makes the oral semaglutide formulation the first GLP-1 pill available to European patients with obesity and overweight conditions, diversifying the delivery methods for the blockbuster drug class.
This regulatory green light addresses a key barrier to entry for many patients who have historically preferred oral medications over injectable treatments.
By offering a pill alternative, Novo Nordisk is positioned to capture a wider segment of the European market, potentially accelerating adoption rates and reinforcing its dominance in the obesity care sector.
The move aligns with growing investor optimism surrounding the company’s pipeline.
Danske Bank recently upgraded its sales forecast for Novo Nordisk’s second quarter, citing robust demand for the company’s oral weight-loss treatment.